ReviewCirculation reports2026
Far-Infrared Therapy: Mechanisms of Action.
Review in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Far-infrared therapy, with wavelengths ranging from 3 to 25 μm, has emerged as a noninvasive photothermal and photobiomodulatory intervention with promising therapeutic applications in cardiovascular medicine, wound healing, and chronic inflammatory diseases. Far-infrared penetrates superficial and subcutaneous tissues, inducing mild, sustained hyperthermia and wavelength-specific molecular signaling. These effects activate mechanosensitive and thermosensitive pathways, including the transient receptor potential channels, phosphoinositide 3-kinase-Akt pathway, and adenosine monophosphate-activated protein kinase pathway. This activation leads to the phosphorylation of endothelial nitric oxide synthase, enhancing nitric oxide bioavailability and vascular homeostasis. In parallel, far-infrared attenuates oxidative stress by suppressing the activity of nicotinamide adenine dinucleotide phosphate oxidase, improving mitochondrial coupling, and activating the nuclear factor erythroid 2-related factor 2-antioxidant response element pathway, thereby increasing the expression of endogenous antioxidant enzymes. The resultant redox shift inhibits nuclear factor kappa B activation, reducing proinflammatory cytokine production, adhesion molecule expression, and leukocyte-endothelium interactions. Additionally, far-infrared promotes macrophage polarization toward an anti-inflammatory M2 phenotype and enhances angiogenic signaling, partly through vascular endothelial growth factor upregulation in a low-inflammatory milieu. Preclinical and clinical studies have shown that these combined antioxidant, anti-inflammatory, vasodilatory, and angiogenic effects contribute to improved microvascular perfusion, endothelial function, and tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.